Details

Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects up to six million people in the U.S., and just as many worldwide have glaucoma-related bilateral blindness. The prevalence of glaucoma is increasing, and more than 100 million people across the globe will have glaucoma by 2040. Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.

By the end of the session the participant will be able to:

• Summarize the most impactful findings at the AAO 2019 meeting relating to glaucoma, including diagnostic testing, therapeutic success, and emerging therapies, and apply that knowledge to patients with different forms of glaucoma
• Recall the results from the Horizon, LiGHT, and OHTS studies
• List conditions that can masquerade as normal-tension glaucoma (NTG) and the role of systemic blood pressure in evaluation and management of NTG
• Summarize the role of the following in glaucoma: hemoglobin video imaging, bimatoprost sustained-release implant, and the microshunt technology

Target Audience:

HCPs including: comprehensive ophthalmologists and retinal specialists; physician assistants and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with glaucoma.